AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22017387 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex anthroposophic remedy (Apis regina tota GL D4, Argentum metallicum D5, Ovaria bovis GL D4), 3 × 10 globuli daily for 12 weeks
Number of subjects: 102
Study 22017387 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 102
Study 22017387 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex remedy for 24 consecutive weeks
Number of subjects: 102
Study 22017387 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (R/R/P)
Number of subjects: 102
Study 22017387 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (P/R/R)
Number of subjects: 102
Study 22017387 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3 (R/P/R)
Number of subjects: 102
Study 19846181 — intervention group
Group type: EXPERIMENTAL
Intervention: small carbohydrate (CH)-rich meal
Number of subjects: 24
Study 19846181 — intervention group
Group type: EXPERIMENTAL
Intervention: large carbohydrate (CH)-rich meal
Number of subjects: 24
Study 19846181 — intervention group
Group type: EXPERIMENTAL
Intervention: fat-rich meal
Number of subjects: 24
Study 19846181 — intervention group
Group type: EXPERIMENTAL
Intervention: more carbohydrate (CH)
Number of subjects: 24
Study 19846181 — intervention group
Group type: COMPARATOR
Intervention: control (well-controlled patients with diabetes)
Number of subjects: 24
Study 17622710 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 different dialyzers differing in biocompatibility and flux, used for 4 weeks
Number of subjects: 15
Study 16245418 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenspiride 160 mg/day for 6 months
Number of subjects: 157
Study 16245418 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157
Study 11832706 — intervention group
Group type: EXPERIMENTAL
Intervention: Hands-on training (low fidelity model)
Number of subjects: 40
Study 11832706 — intervention group
Group type: EXPERIMENTAL
Intervention: Hands-on training (high fidelity model)
Number of subjects: 40
Study 11832706 — intervention group
Group type: COMPARATOR
Intervention: Didactic session
Number of subjects: 40
Study 12476070 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy for 14 days
Number of subjects: 21
Study 9829492 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron therapy (Ferric saccharate, 100 mg dose, administered postdialysis on five consecutive dialysis sessions for 2 weeks)
Number of subjects: 50
Study 9829492 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ascorbic acid therapy (300 mg dose, administered thrice a week for 8 weeks)
Number of subjects: 50
Study 9829492 — intervention group
Group type: COMPARATOR
Intervention: Control group (Control I and Control II, haematocrit > 30%, no adjuvant therapy)
Number of subjects: 50
Study 8137272 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of oncogene mutations in sputum using a polymerase chain reaction-based assay.
Number of subjects: 15
Study 8137272 — intervention group
Group type: EXPERIMENTAL
Intervention: Earliest detection of a clonal population of cancer cells in sputum.
Number of subjects: 15
Study 2667926 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous basal-rate intravenous insulin infusion
Number of subjects: 10
Study 2667926 — intervention group
Group type: COMPARATOR
Intervention: Single daily injections of ultralente insulin
Number of subjects: 10
Study 2667926 — intervention group
Group type: COMPARATOR
Intervention: Single daily injections of lente insulin
Number of subjects: 10
Study 996681 — intervention group
Group type: EXPERIMENTAL
Intervention: 220 mg zinc sulphate
Number of subjects: 0
Study 996681 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml bicitropeptide
Number of subjects: 0
Study 7014104 — intervention group
Group type: EXPERIMENTAL
Intervention: Amineptine (mean 180 mg, range 100-300 mg)
Number of subjects: 62
Study 7014104 — intervention group
Group type: COMPARATOR
Intervention: Clomipramine (mean 84 mg, range 50-150 mg)
Number of subjects: 62
Study 7014104 — intervention group
Group type: EXPERIMENTAL
Intervention: Amineptine
Number of subjects: 62
Study 31356483 — intervention group
Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation exercises in addition to repositioning maneuvers (experimental group, n = 17)
Number of subjects: 32
Study 31356483 — intervention group
Group type: COMPARATOR
Intervention: Repositioning maneuvers only (control group, n = 15)
Number of subjects: 32
Study 29356603 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg dexketoprofen trometamol (DKT)
Number of subjects: 100
Study 29356603 — intervention group
Group type: COMPARATOR
Intervention: 500 mg vitamin C (PLACEBO)
Number of subjects: 100
Study 27821382 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous eculizumab (900 mg/day)
Number of subjects: 33
Study 27821382 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 24965720 — intervention group
Group type: EXPERIMENTAL
Intervention: NHA-Burden Prognostic tool
Number of subjects: 1610
Study 24965720 — intervention group
Group type: EXPERIMENTAL
Intervention: NHA-Depression Prognostic tool
Number of subjects: 1610
Study 22168326 — intervention group
Group type: COMPARATOR
Intervention: 0.1% topical adapalene gel for 4 weeks (Group A)
Number of subjects: 158
Study 22168326 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% topical adapalene gel and 600 mg oral faropenem for 2 weeks followed by 0.1% topical adapalene gel alone for 2 weeks (Group B)
Number of subjects: 158
Study 22168326 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% topical adapalene gel and 600 mg oral faropenem for 4 weeks (Group C)
Number of subjects: 158
Study 19937983 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic donor nephrectomy (LDN)
Number of subjects: 84
Study 19937983 — intervention group
Group type: COMPARATOR
Intervention: Short-incision open donor nephrectomy (ODN)
Number of subjects: 84
Study 18842788 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient supplementation (daily tablet containing 15 micronutrients at just above the recommended nutrient intake)
Number of subjects: 500
Study 18842788 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 500
Study 18842788 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient supplementation
Number of subjects: 500
Study 16053527 — intervention group
Group type: EXPERIMENTAL
Intervention: self‐help manual and enhanced stage‐based counselling
Number of subjects: 918
Study 16053527 — intervention group
Group type: EXPERIMENTAL
Intervention: self‐help manual, enhanced stage‐based counselling and use of an interactive computer program
Number of subjects: 918
Study 16053527 — intervention group
Group type: COMPARATOR
Intervention: standard care
Number of subjects: 918
Study 12209296 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacker device (spiral titanium tacks)
Number of subjects: 34
Study 12209296 — intervention group
Group type: COMPARATOR
Intervention: Running 2-0 polypropylene suture
Number of subjects: 34
Study 10487375 — intervention group
Group type: COMPARATOR
Intervention: Diet-only group (D; N = 8)
Number of subjects: 35
Study 10487375 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet group with aerobic exercise (DE; N = 11)
Number of subjects: 35
Study 10487375 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet group with aerobic and strength training (DES; N = 10)
Number of subjects: 35
Study 8923125 — intervention group
Group type: EXPERIMENTAL
Intervention: Milnacipran (50 mg twice a day)
Number of subjects: 0
Study 8923125 — intervention group
Group type: COMPARATOR
Intervention: Tricyclic Antidepressants (TCAs)
Number of subjects: 0
Study 8923125 — intervention group
Group type: EXPERIMENTAL
Intervention: Milnacipran
Number of subjects: 0
Study 1679243 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 1 mg
Number of subjects: 12
Study 1679243 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg
Number of subjects: 12
Study 1679243 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam 2 mg (single oral dose)
Number of subjects: 12
Study 1679243 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6415364 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone treatment with 4 mg oestradiol
Number of subjects: 131
Study 6415364 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone treatment with 2 mg oestradiol
Number of subjects: 131
Study 6415364 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone treatment with 1 mg oestradiol
Number of subjects: 131
Study 6415364 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study 6415364 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal of hormone treatment
Number of subjects: 131
Study 30320964 — intervention group
Group type: EXPERIMENTAL
Intervention: Belimumab 10 mg/kg every 28 days plus standard therapy
Number of subjects: 268
Study 29624575 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg/day)
Number of subjects: 30
Study 29624575 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 26294070 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose isoflavone aglycone (25 mg/day)
Number of subjects: 90
Study 26294070 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 25248831 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive education group (Group I)
Number of subjects: 96
Study 25248831 — intervention group
Group type: COMPARATOR
Intervention: Pamphlet education group (Group II)
Number of subjects: 96
Study 22974080 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile Diabetes Education Teams (MDETs) intervention
Number of subjects: 1200
Study 22974080 — intervention group
Group type: COMPARATOR
Intervention: Control group (clusters randomized to receive intervention later)
Number of subjects: 1200
Study 20067326 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 5% medicated plaster
Number of subjects: 0
Study 20067326 — intervention group
Group type: COMPARATOR
Intervention: Pregabalin
Number of subjects: 0
Study 20067326 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 5% medicated plaster (realistic usage)
Number of subjects: 0
Study 17400850 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 200 mg orally and misoprostol 800 mcg vaginally administered simultaneously
Number of subjects: 1128
Study 17400850 — intervention group
Group type: COMPARATOR
Intervention: Mifepristone 200 mg orally and misoprostol 800 mcg vaginally administered 24 hours apart
Number of subjects: 1128
Study 16142748 — intervention group
Group type: COMPARATOR
Intervention: HuMax-IL15
Number of subjects: 30
Study 12729424 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole (200 mg intravenously every 12 hours for 2 days followed by 200 mg intravenously every 24 hours or a 200‐mg oral solution every 12 hours)
Number of subjects: 140
Study 12729424 — intervention group
Group type: COMPARATOR
Intervention: Fluconazole (400 mg intravenously or orally every 24 hours)
Number of subjects: 140
Study 12729424 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole
Number of subjects: 140
Study 12729424 — intervention group
Group type: COMPARATOR
Intervention: Fluconazole
Number of subjects: 140
Study 10717733 — intervention group
Group type: EXPERIMENTAL
Intervention: Insecticide-treated materials (ITMs) with lambdacyhalothrin
Number of subjects: 19
Study 10717733 — intervention group
Group type: COMPARATOR
Intervention: General health education (Control)
Number of subjects: 19
Study 8952557 — intervention group
Group type: COMPARATOR
Intervention: Tetracycline (20 mg/kg [maximum of 2 g] in 50 mL of normal saline)
Number of subjects: 60
Study 8952557 — intervention group
Group type: COMPARATOR
Intervention: Bleomycin (1 U/kg [maximum of 60 U] in 50 mL of normal saline)
Number of subjects: 60
Study 8952557 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of tetracycline (20 mg/kg [maximum of 2 g] in 40 mL of normal saline) and bleomycin (1 U/kg [maximum of 60 U] in 30 mL of normal saline)
Number of subjects: 60
Study 1798305 — intervention group
Group type: EXPERIMENTAL
Intervention: Active recovery (cycling at 30% VO2max)
Number of subjects: 5
Study 1798305 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive recovery (sitting quietly)
Number of subjects: 5
Study 1798305 — intervention group
Group type: COMPARATOR
Intervention: Control test (no recovery)
Number of subjects: 5
Study 7381634 — intervention group
Group type: EXPERIMENTAL
Intervention: Cloxacillin administered intravenously for ten days
Number of subjects: 22
Study 7381634 — intervention group
Group type: COMPARATOR
Intervention: Carbenicillin plus gentamicin administered intravenously for ten days
Number of subjects: 22
Study 30381936 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer education intervention (intensive three-day training for peer educators)
Number of subjects: 20
Study 26984117 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-led and community-implemented CBPR strategy for recruiting
Number of subjects: 160
Study 25320597 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone 8mg
Number of subjects: 108
Study 25320597 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of dexamethasone 8mg and ondansetron 4mg
Number of subjects: 108
Study 22464089 — intervention group
Group type: EXPERIMENTAL
Intervention: True noninvasive limb cover
Number of subjects: 57
Study 22464089 — intervention group
Group type: COMPARATOR
Intervention: Sham noninvasive limb cover
Number of subjects: 57
Study 20445999 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with deep surgical site infections (SSI) following spinal fusion
Number of subjects: 1
Study 20445999 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with diabetes
Number of subjects: 1
Study 20445999 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 1
Study 20445999 — intervention group
Group type: COMPARATOR
Intervention: Uninfected patients (control group)
Number of subjects: 1
Study 18762508 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding
Number of subjects: 101
Study 18762508 — intervention group
Group type: COMPARATOR
Intervention: Oral sucrose solution (1 mL of 25% sucrose solution)
Number of subjects: 101
Study 15785924 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2% applied topically, twice a day for 4-48 hours before laser treatment and continued for 1 month.
Number of subjects: 20
Study 15785924 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matched control group), applied topically, twice a day for 4-48 hours before laser treatment and continued for 1 month.
Number of subjects: 20
Study 12498584 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (increased bedroom temperature by at least 3 degrees C)
Number of subjects: 28
Study 12498584 — intervention group
Group type: COMPARATOR
Intervention: Control group (no temperature increase)
Number of subjects: 28
Study 10363725 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA antigen B63 in patients with HPV types other than HPV 16 or 18
Number of subjects: 288
Study 10363725 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA antigen B55 in patients negative for all HPV types
Number of subjects: 288
Study 10363725 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA antigen DR15
Number of subjects: 288
Study 10363725 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA antigen DR3 in patients with HPV types other than HPV 16 or 18
Number of subjects: 288
Study 10363725 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA antigen DR11 among HPV 16 positive patients
Number of subjects: 288
Study 10363725 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA antigen DR13
Number of subjects: 288
Study 10363725 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA antigens DR15 and DQ4 in CIN patients
Number of subjects: 288
Study 7738792 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone bolus single dose (0.25‐2.0 mg/kg)
Number of subjects: 0
Study 7738792 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone continuous infusion (4‐h)
Number of subjects: 0
Study 7738792 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone bolus multiple doses (four consecutive doses at 3‐h intervals)
Number of subjects: 0
Study 7738792 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone (various administrations)
Number of subjects: 0
Study 7738792 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of pharmacokinetic parameters in Japanese and Caucasian volunteers
Number of subjects: 0
Study 2028004 — intervention group
Group type: EXPERIMENTAL
Intervention: Ionic contrast media
Number of subjects: 101
Study 2028004 — intervention group
Group type: COMPARATOR
Intervention: Nonionic (low‐osmolality) contrast agents
Number of subjects: 101
Study 6797454 — intervention group
Group type: EXPERIMENTAL
Intervention: MR 1268 2.5 mg
Number of subjects: 6
Study 6797454 — intervention group
Group type: EXPERIMENTAL
Intervention: MR 1268 5 mg
Number of subjects: 6
Study 6797454 — intervention group
Group type: EXPERIMENTAL
Intervention: MR 1268 10 mg
Number of subjects: 6
Study 6797454 — intervention group
Group type: EXPERIMENTAL
Intervention: MR 1268 20 mg
Number of subjects: 6
Study 31014702 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D HUD surgical platform
Number of subjects: 39
Study 31014702 — intervention group
Group type: COMPARATOR
Intervention: SOM
Number of subjects: 39
Study 28415943 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mL of 0.5% bupivacaine (Group B, n = 30)
Number of subjects: 90
Study 28415943 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mL of 0.5% levobupivacaine (Group L, n = 30)
Number of subjects: 90
Study 28415943 — intervention group
Group type: COMPARATOR
Intervention: Saline as a placebo (Group C, n = 30)
Number of subjects: 90
Study 25903217 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous alcohol self-administration (up to a maximum BAC of 160 mg% in study 1 and 120 mg% in study 2)
Number of subjects: 78
Study 25903217 — intervention group
Group type: COMPARATOR
Intervention: Non-exposed age-matched control group (42 participants)
Number of subjects: 78
Study 23574969 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (10 mg)
Number of subjects: 26
Study 23574969 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 26
Study 23574969 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 26
Study 21329577 — intervention group
Group type: EXPERIMENTAL
Intervention: Anhedonia (lack of pleasure)
Number of subjects: 82
Study 21329577 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 82
Study 19629797 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behaviour therapy (CBT)
Number of subjects: 211
Study 16687482 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Number of subjects: 180
Study 16687482 — intervention group
Group type: EXPERIMENTAL
Intervention: Brace only
Number of subjects: 180
Study 16687482 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of physiotherapy and brace
Number of subjects: 180
Study 15293491 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary back school programme (Roessingh Back Rehabilitation Programme, RRP)
Number of subjects: 163
Study 15293491 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 163
Study 11420761 — intervention group
Group type: EXPERIMENTAL
Intervention: wet/cold profile
Number of subjects: 440
Study 11420761 — intervention group
Group type: EXPERIMENTAL
Intervention: wet/warm profile
Number of subjects: 440
Study 11420761 — intervention group
Group type: EXPERIMENTAL
Intervention: dry/cold profile
Number of subjects: 440
Study 11420761 — intervention group
Group type: EXPERIMENTAL
Intervention: dry/warm profile
Number of subjects: 440
Study 9165176 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate aerobic exercise added to medical antihypertensive therapy
Number of subjects: 0
Study 9165176 — intervention group
Group type: COMPARATOR
Intervention: Medical antihypertensive therapy (indapamide +/- verapamil +/- enalapril)
Number of subjects: 0
Study 8210016 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 48
Study 8210016 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone
Number of subjects: 48
Study 2681547 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard therapy
Number of subjects: 111
Study 2681547 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study 31760132 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 340
Study 31760132 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 340
Study 31173551 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib
Number of subjects: 553
Study 31173551 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 553
Study 25799085 — intervention group
Group type: EXPERIMENTAL
Intervention: Perflubron-induced lung growth (PILG)
Number of subjects: 16
Study 25799085 — intervention group
Group type: COMPARATOR
Intervention: Conventional ventilation
Number of subjects: 16
Study 21899792 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure plus reward (E + R)
Number of subjects: 185
Study 21899792 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure only (EO)
Number of subjects: 185
Study 21899792 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 185
Study 21620416 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 as add-on therapy to subcutaneous interferon β-1a
Number of subjects: 0
Study 21620416 — intervention group
Group type: COMPARATOR
Intervention: Placebo as add-on therapy to subcutaneous interferon β-1a
Number of subjects: 0
Study 18980263 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (1.75 mg/kg) three times daily for four consecutive weeks
Number of subjects: 15
Study 18980263 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 17164069 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol chewing gum (n=61)
Number of subjects: 173
Study 17164069 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine/xylitol/sorbitol chewing gum (n=55)
Number of subjects: 173
Study 17164069 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium fluoride/xylitol/sorbitol chewing gum (n=57)
Number of subjects: 173
Study 14583369 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol 5 to 10 mg once daily
Number of subjects: 90
Study 14583369 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 12.5 to 25 mg twice daily
Number of subjects: 90